**FORM      10-QSB**

| [X]                | Quarterly                Report pursuant to Section 13 or 15(d) of the Securities Exchange                Act of                1934                                                                              |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|               |                                                                                                                                                                                                              |
|               | For                the quarterly period ended September                30, 2005                                                                                                                                   |
|               |                                                                                                                                                                                                              |
| [                ] | Transition                Report pursuant to 13 or 15(d) of the Securities Exchange Act of                1934                                                                                                    |
|               |                                                                                                                                                                                                              |
|               |                                   For the transition period  _________                to                __________ |
|               |                                                                                                                                                                                                              |
|               | Commission                File Number: 001-14297                                                                                                                                                                  |

| Nevada                                                                        | 86-0907471                                       |
|-------------------------------------------------------------------------------|--------------------------------------------------|
| (State                or other jurisdiction of incorporation or organization) | (IRS                Employer Identification No.) |

| 301                North Canon Drive, Suite 207, Beverly Hills, California                90210 |
|-------------------------------------------------------------------------------------------------|
| (Address                of principal executive offices)                                         |

| 310-205-9907                                                                                                     |
|------------------------------------------------------------------------------------------------------------------|
| (Issuer’s                telephone number)                                                                 |
|  301                North Canon Drive, Suite 328, Beverly                Hills, California 90210            |
| (Former                name, former address and former fiscal year, if changed since last                report) |

----

Table          of Contents

|                                                   | TABLE                OF CONTENTS                                                          |   Page |
|--------------------------------------------------------|-------------------------------------------------------------------------------------------|------------------|
| PART                I - FINANCIAL INFORMATION     |
| Item                1:                                 | Financial                Statements                                                       | 3                |
| Item                2:                                 | Plan                of Operation                                                          | 4                |
| Item                3:                                 | Controls                and Procedures                                                    | 9                |
|  PART                II - OTHER INFORMATION  |
| Item                1:                                 | Legal                Proceedings                                                          | 10               |
| Item                2:                                 | Unregistered                Sales of Equity Securities and Use                of Proceeds | 10               |
| Item                3:                                 | Defaults                Upon Senior Securities                                            | 10               |
| Item                4:                                 | Submission                of Matters to a Vote of Security                Holders         | 10               |
| Item                5:                                 | Other                Information                                                          | 10               |
| Item                6:                                 | Exhibits                                                                                  | 10               |

----

Table          of Contents

**PART      I - FINANCIAL INFORMATION**

**Item      1.** **     Financial      Statements**

| (a)   | Balance                Sheet as of September 30,                2005. |
|-----------------|-----------------------------------------------------------------------|

| (b)   | Statements                of Operations for the three and                nine month periods ended September 30, 2005 and 2004, and from                inception; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Statements                of Cash Flow for the nine month periods ended                September 30, 2005 and 2004, and from inception; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | Notes                to Consolidated Financial                Statements. |
|-----------------|---------------------------------------------------------------------------|

----

Table          of Contents

| **DAVI                  SKIN, INC.**                                             |   |    |                                |
|----------------------------------------------------------------------------------|--------|---------|-------------------------------------|
| **(formerly                  MW Medical, Inc.)**                                 |   |    |                                |
| **(A                  Developmental Stage Company)**                             |   |    |                                |
|                                                                             |   |    |                                |
| **CONSOLIDATED                  BALANCE SHEET**                                  |   |    |                                |
|                                                                             |   |    |                                |
|                                                                             |   |    |                                |
| **ASSETS**                                                                       |   |    | **As                  Of**          |
|                                                                             |   |    | **Sept                  30,**  |
| Current                  Assets                                                  |   |    | **2005**                            |
| Cash                                                                             |   |  $ | 34,145                              |
| Certificate                  of Deposit                                          |   |    | 1,831,086                           |
| Prepaid                  Expenses                                                |   |    | 3,162                               |
|                                                                             |   |    |                                |
| TOTAL                  CURRENT ASSETS                                            |   |  $ | 1,868,393                           |
|                                                                             |   |    |                                |
| Fixed                  Assets, net of accumulated depreciation of $12,785        |   |    | 47,627                              |
|                                                                             |   |    |                                |
| Other                  Assets                                                    |   |    |                                |
| Deposits                                                                         |   |    | 11,505                              |
|                                                                             |   |    |                                |
|                                                                             |   |    |                                |
| TOTAL                  ASSETS                                                    |   |  $ | 1,927,525                           |
|                                                                             |   |    |                                |
| LIABILITIES                  AND STOCKHOLDERS' EQUITY                            |   |    |                                |
|                                                                             |   |    |                                |
| Current                  Liabilities                                             |   |    |                                |
| Accounts                  payable                                                |   |    | 45,727                              |
| Short                  term notes payable                                        |   |    | -                                   |
| Notes                  payable- related parties                                  |   |    | 225,000                             |
|                                                                             |   |    |                                |
| TOTAL                  CURRENT LIABILITIES                                       |   |  $ | 270,727                             |
|                                                                             |   |    |                                |
| Stockholders'                  Equity                                            |   |    |                                |
| Preferred                  stock; $.001 par value; 10,000,000 shares authorized, |   |    |                                |
| and                  no shares issued and outstanding                            |   |    | -                                   |
| Common                  stock; $.001 par value; 90,000,000 shares authorized,    |   |    |                                |
| 11,512,618                  shares issued and outstanding                        |   |    | 11,512                              |
| Additional                  paid-in capital                                      |   |    | 4,382,490                           |
| Accumulated                  deficit during developmental stage                  |   |    | (2,656,996)                         |
| Prepaid                  consulting expense                                      |   |    | (80,208)                            |
| Stock                  subscriptions receivable                                  |   |    | -                                   |
|                                                                             |   |    |                                |
| TOTAL                  STOCKHOLDERS' EQUITY                                      |   |  $ | 1,656,798                           |
|                                                                             |   |    |                                |
| TOTAL                  LIABILITIES AND STOCKHOLDERS' EQUITY                      |   |  $ | 1,927,525                           |

----

Table          of Contents

| **DAVI                  SKIN, INC.**                                          |                                                    |       |   |                                             |        |   |                                          |      |   |
|-------------------------------------------------------------------------------|---------------------------------------------------------|------------|--------|--------------------------------------------------|-------------|--------|-----------------------------------------------|-----------|--------|
| **(formerly                  MW Medical, Inc.)**                              |                                                    |       |   |                                             |        |   |                                          |      |   |   |   |   |   |   |
| **(A                  Developmental Stage Company)**                          |                                                    |       |   |                                             |        |   |                                          |      |   |   |   |   |   |   |
|                                                                          |                                                    |       |   |                                             |        |   |                                          |      |   |   |   |   |   |   |
| **CONSOLIDATED                  STATEMENT OF OPERATIONS**                     |                                                    |       |   |                                             |        |   |                                          |      |   |   |   |   |   |   |
|                                                                          |                                                    |       |   |                                             |        |   |                                          |      |   |   |   |   |   | **From                  the Date of **  |
|                                                                          |  **Three                  months ended Sept. 30,** |       |   | **Nine                  months ended Sept. 30,** |        |   | **inception                  March 21, 2004** |
|                                                                          |                                                    | **2005**   |   |                                             | **2004**    |   |                                          | **2005**  |   |   | **2004** |   |   | **through                  Sept. 30, 2005** |
|                                                                          |                                                    |       |   |                                             |        |   |                                          |      |   |   |   |   |   |   |
| Revenues                                                                      |                                                    | -          |   |                                             | -           |   |                                          | -         |   |   | - |   |   | - |
| Cost                  of revenues                                             |                                                    | -          |   |                                             | -           |   |                                          | -         |   |   | - |   |   | - |
| Gross                  Profit (Loss)                                          |                                                    | -          |   |                                             | -           |   |                                          | -         |   |   | - |   |   | - |
| Operating                  Expenses                                           |                                                    |       |   |                                             |        |   |                                          |      |   |   |   |   |   |   |
| Selling,                  general and administrative                          |                                                    | 208,392    |   |                                             | 52,126      |   |                                          | 490,763   |   |   | 227,882 |   |   | 1,312,017 |
| Depreciation                                                                  |                                                    | 4,288      |   |                                             | 1,229       |   |                                          | 10,303    |   |   | 2,228 |   |   | 13,712 |
| Consulting                  Fees                                              |                                                    | 19,173     |   |                                             | 716,848     |   |                                          | 246,275   |   |   | 716,848 |   |   | 952,115 |
| Professional                  Fees                                            |                                                    | 55,949     |   |                                             | 524,784     |   |                                          | 130,026   |   |   | 524,784 |   |   | 180,458 |
| Total                  oper. Expenses                                         |                                                    | 287,802    |   |                                             | 1,294,987   |   |                                          | 877,367   |   |   | 1,471,742 |   |   | 2,458,302 |
|                                                                          |                                                    |       |   |                                             |        |   |                                          |      |   |   |   |   |   |   |
| (Loss)                  From operations                                       |                                                    | (287,802)  |   |                                             | (1,294,987) |   |                                          | (877,367) |   |   | (1,471,742) |   |   | (2,458,302) |
|                                                                          |                                                    |       |   |                                             |        |   |                                          |      |   |   |   |   |   |   |
| Other                  Income (expenses)                                      |                                                    |       |   |                                             |        |   |                                          |      |   |   |   |   |   |   |
| Interest                  expenses                                            |                                                    | (5,000)    |   |                                             | (5,000)     |   |                                          | (15,005)  |   |   | (5,000) |   |   | (25,005) |
| Interest                  income                                              |                                                    | 6,374      |   |                                             | 2,519       |   |                                          | 16,701    |   |   | 3,393 |   |   | 21,898 |
| Loss                  on sale of assets                                       |                                                    | (534)      |   |                                             |        |   |                                          | (534)     |   |   |   |   |   | (534) |
| Sublease                  rent                                                |                                                    | 3,000      |   |                                             |        |   |                                          | 3,000     |   |   |   |   |   | 3,000 |
| Total                  other income (expense)                                 |                                                    | 3,840      |   |                                             | (2,481)     |   |                                          | 4,162     |   |   | (1,607) |   |   | (641) |
|                                                                          |                                                    |       |   |                                             |        |   |                                          |      |   |   |   |   |   |   |
| NET                  (LOSS)                                                   | $                                                       | (283,962)  |   |  $                                          | (1,297,468) |   | $                                             | (873,205) |   | $ | (1,473,349) |   | $ | (2,458,943) |
|                                                                          |                                                    |       |   |                                             |        |   |                                          |      |   |   |   |   |   |   |
| Basic                  (loss) per common share                                | $                                                       | (0.02)     |   |  $                                          | (0.02)      |   | $                                             | (0.09)    |   | $ | (0.02) |   |   |   |
|                                                                          |                                                    |       |   |                                             |        |   |                                          |      |   |   |   |   |   |   |
| Diluted                  loss per common share                                | $                                                       | (0.02)     |   |  $                                          | (0.02)      |   | $                                             | (0.09)    |   | $ | (0.02) |   |   |   |
|                                                                          |                                                    |       |   |                                             |        |   |                                          |      |   |   |   |   |   |   |
| Basic                  and diluted weighted average common shares outstanding |                                                    | 11,368,716 |   |                                             | 9,606,527   |   |                                          | 9,216,205 |   |   | 9,606,527 |   |   |   |

----

Table          of Contents

| **DAVI                  SKIN, INC.**                                                   |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
|----------------------------------------------------------------------------------------|--------|---------|--------------------------------------------------------------------------------|--------|---------|--------------------------------------------------------------------------------|--------|---------|--------------------------------------------------------------------------------------------------------|
| **(formerly                  MW Medical, Inc.)**                                       |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| **(A                  Developmental Stage Company)**                                   |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
|                                                                                   |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| **CONSOLIDATED                  STATEMENT OF CASH FLOWS  (UNAUDITED)**  |   |    |                                                                           |   |    |                                                                           |
| ** **                                                                             |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
|                                                                                   |   |    | For                  the nine months                  ended September 30, 2005 |   |    | For                  the nine months                  ended September 30, 2004 |   |    | From                  the Date of inception March 21, 2004 through September 30,                  2005 |
|                                                                                   |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| **OPERATING                  ACTIVITIES**                                              |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| Net                  (loss)                                                            |   |  $ | (873,205)                                                                      |   |  $ | (1,473,349)                                                                    |   |  $ | (2,458,943)                                                                                            |
| Adjustments                  to reconcile net (loss) to net                            |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| cash                  used in operating activities:                                    |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| Prepaid                  consulting expense                                            |   |    | 34,376                                                                         |   |    | 0                                                                              |   |    | (80,208)                                                                                               |
| Stock                  based compensation & expenses                               |   |    | 0                                                                              |   |    | 1,246,005                                                                      |   |    | 1,160,026                                                                                              |
| Depreciation                  and amortization                                         |   |    | 10,303                                                                         |   |    | 2,229                                                                          |   |    | 12,785                                                                                                 |
| Accrued                  interest                                                      |   |    | 15,000                                                                         |   |    | 5,000                                                                          |   |    | 25,000                                                                                                 |
|                                                                                   |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| Changes                  in operating assets and liabilities:                          |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| Prepaid                  Expenses                                                      |   |    | 6,213                                                                          |   |    | (12,450)                                                                       |   |    | (3,162)                                                                                                |
| Deposits                                                                               |   |    | (7,805)                                                                        |   |    | 0                                                                              |   |    | (11,505)                                                                                               |
| Accounts                  Payable                                                      |   |    | 6,567                                                                          |   |    | 26,820                                                                         |   |    | 45,727                                                                                                 |
|                                                                                   |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
|                                                                                   |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
|                                                                                   |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| Net                  Cash used by                                                 |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| Operating                  Activities                                                  |   | $       | (808,551)                                                                      |   |  $ | (205,745)                                                                      |   |  $ | (1,310,286)                                                                                            |
|                                                                                   |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
|                                                                                   |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| **INVESTING                  ACTIVITIES**                                              |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| Cash                  flow from investing activities:                                  |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| Change                  in certificate of deposit                                      |   |    | (1,518,134)                                                                    |   |    | (500,875)                                                                      |   |    | (1,831,086)                                                                                            |
| Sale                  of fixed assets                                                  |   |    | 2,273                                                                          |   |    | -                                                                              |   |    | 2,273                                                                                                  |
| Purchase                  of fixed assets                                              |   |    | (24,500)                                                                       |   |    | (25,520)                                                                       |   |    | (62,685)                                                                                               |
| Net                  cash used by                                                      |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| investing                  activities                                                  |   | $       | (1,540,361)                                                                    |   | $       | (526,395)                                                                      |   | $       | (1,891,498)                                                                                            |
| **FINANCING                  ACTIVITIES**                                              |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| Cash                  flows from financing activities                                  |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| Proceeds                  from stock transactions                                      |   |    | 1,887,426                                                                      |   |    | 765,348                                                                        |   |    | 3,035,929                                                                                              |
| Short                  term notes payable                                              |   |    | (10,500)                                                                       |   |    | -                                                                              |   |    | 0                                                                                                      |
| Notes                  payable- related party                                          |   |    | -                                                                              |   |    | -                                                                              |   |    | 200,000                                                                                                |
| Net                  cash provided by                                                  |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| financing                  activities                                                  |   | $       | 1,876,926                                                                      |   | $       | 765,348                                                                        |   | $       | 3,235,929                                                                                              |
|                                                                                   |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| Net                  change in cash and cash equivalents                               |   |    | (471,986)                                                                      |   |    | 33,208                                                                         |   |    | 34,145                                                                                                 |
|                                                                                   |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                   |
| Cash                  beginning of period                                              |   |    | 506,131                                                                        |   |    | 0                                                                              |   |    | -                                                                                                      |
|                                                                                   |   |    |                                                                           |   |    |                                                                           |   |    |                                                                                                        |
| Cash                  end of period                                                    |   | $       | 34,145                                                                         |   | $       | 33,208                                                                         |   | $       | 34,145                                                                                                 |

----

Table          of Contents

**DAVISKIN,        INC.**

**(formerly        MW Medical, Inc.)**

**(A        Development State Company)**

 

**        NOTES        TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

 

1.                BASIS OF PRESENTATION

 

The        accompanying unaudited consolidated financial statements of Davi Skin, Inc.        ("Company") have been prepared in accordance with Securities and Exchange        Commission requirements for interim financial statements. Therefore, they        do not        include all of the information and footnotes required by accounting principles        generally accepted in the United States for complete financial statements.        The        financial statements should be read in conjunction with the Form 10-KSB of        the        Company for the year ended December 31, 2004. 

 

The        interim financial statements present the balance sheet, statements of        operations, stockholders' equity and cash flows of the Company. The financial        statements have been prepared in accordance with accounting principles generally        accepted in the United States.

 

 The        interim financial information is unaudited. In the opinion of management,        all        adjustments necessary to present fairly the financial position as of September        30, 2005 and the results of operations, stockholders' equity and cash flows        presented herein have been included in the financial statements. Interim        results        are not necessarily indicative of results of operations for the full year.        

 

The        preparation of financial statements in conformity with accounting principles        generally accepted in the United States requires management to make estimates        and assumptions that affect the reported amounts of assets and liabilities        and        disclosure of contingent assets and liabilities at the date of the financial        statements and the reported amounts of revenues and expenses during the        reporting period. Actual results could differ from those estimates. 

 

2.                DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT        POLICIES

 

Description        of business. Davi Skin, Inc., formerly MW Medical, Inc., (referred to as the“Company”) is involved inthe establishment and development of an all-natural        grape-based skin care line. 

 

History.        On June 21, 2004, the Companycompleted and closed a Plan of Merger and        Reorganization Agreement (“Merger Transaction”) with Davi Skin, Inc. (“Davi”),        aprivately owned company, whereby both parties agreed that a subsidiary of        the        Company would merge into and with Davi and become a wholly owned subsidiary        of        the Company.  As consideration for this merger transaction, the Company        issued 9,768,327 shares of its common stock in exchange for all the outstanding        common stock of Davi on a one-for-one share exchange basis.  The Agreement        further provided forCompany’s officers and directors were to resign and the        board of directors of Davi would become the board of directors for the        Company.  This transaction has been accounted for as a recapitalization        or        reverse merger whereby Davi would be considered the accounting acquirer**,**and the accounting history of the acquirer would be carried        forward as        the history for the Company and no goodwill would be recorded.         Accordingly, the accompanying financial statements reflect the history of        Davi        from its date incorporation of March 21, 2004 (incorporated in the State        of        Nevada).  Prior to the merger transaction, the Company had 645,033        shares        of its common stock outstanding, $1,922 in accounts payable, $200,000 in        a note        payable to a related party and no assets.

----

Table          of Contents

**DAVISKIN,      INC.**

**(formerly      MW Medical, Inc.)**

**(A      Development State Company)**

 

**        NOTES      TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(continued)**

 

2.              DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES

                 (continued)

 

 

Going        concern.  The accompanying financial statements have been prepared on        a        going concern basis, which contemplates the realization of assets and the        satisfaction of liabilities in the normal course of business. The Company        has        incurred cumulative net losses of $2,458,943 since its inception and may        require        additional capital for its operational activities.  The Company’s ability        to raise additional capital through the future issuances of the common stock        is        unknown.  Obtaining additional financing and attainingprofitable operations        are necessary for the Company to continue operations.  The ability        to        successfully resolve these factors raise substantial doubt about the Company’s        ability to continue as a going concern.  The consolidated financial        statements of the Company do not include any adjustments that may result        from        the outcome of these aforementioned uncertainties.

 

Definition        of fiscal year. The Company’s fiscal year end is December 31.

 

Use        of        estimates. The preparation of consolidated financial statements in        conformity with accounting principles generally accepted in the United States        requires management to make estimates and assumptions that affect the reported        amounts of assets and liabilities and disclosure of contingent assets and        liabilities at the date of the consolidated financial statements and the        reported amounts of revenue and expenses during the reporting period. Actual        results could differ from those estimates.

 

Revenue        recognition. Revenues are recognized when services are rendered and/or        delivered.  Costs and expenses are recognized during the period in        which        they are incurred.

 

Cash        and Cash Equivalents. The Company considers all highly liquid short-term        investments, with original maturities of three months or less, to be cash        equivalents.  Such cash equivalents generally are part of the Company’s        cash management activities rather than part of its operating, investing,        and        financing activities.  Changes in the market value of cash equivalents        result in gains or losses that are recognized in the income statement in        the        period in which they occur.

 

Fixed        assets. Fixed assets are stated at cost less accumulated depreciation.        Depreciation is provided principally on the straight-line method over the        estimated useful lives of the assets, which are generally 3 to 10 years.        The        cost of repairs and maintenance is charged to expense as incurred. Expenditures        for property betterments and renewals are capitalized. Upon sale or other        disposition of a depreciable asset, cost and accumulated depreciation are        removed from the accounts and any gain or loss is reflected in other income        (expense).

 

----

Table            of Contents

 

**DAVISKIN,        INC.**

**(formerly        MW Medical, Inc.)**

**(A        Development State Company)**

 

**        NOTES        TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(continued)**

 

2.                DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES        

                   (continued)

 

Fixed        Assets (continued)

The        Company periodically evaluates whether events and circumstances have occurred        that may warrant revision of the estimated useful life of fixed assets or        whether the remaining balance of fixed assets should be evaluated for possible        impairment. The Company uses an estimate of the related un-discounted cash        flows        over the remaining life of the fixed assets in measuring their        recoverability.

 

Fair        value of financial instruments. Statement of Financial Accounting Standards        (“SFAS”) No. 107, “Disclosure About Fair Value of Financial Instruments”,        requires the Company to disclose, when reasonably attainable, the fair market        values of its assets and liabilities, which are deemed to be financial        instruments.  The carrying amounts and estimated fair values of the        Company’s financial instruments approximate their fair value due to        theirshort-term nature.

 

Earnings      (loss) per share - Basic earnings (loss) per share exclude any dilutive      effects of options, warrants and convertible securities. Basic earnings (loss)      per share is computed using the weighted-average number of outstanding common      shares during the applicable period. Diluted earnings (loss) per share is      computed using the weighted-average number of common and common stock equivalent      shares outstanding during the period. Common stock equivalent shares are      excluded from the computation if their effect is antidilutive.  Stock      options representing 398,800 common shares were excluded from the computation      because the effect was antidilutive.  Stock option are antidilutive      when      the results from operations are a net loss, as is the case for the for the      period ended September 30, 2005 and from inception to September 30, 2005, or      when the exercise price of the options is greater than the average market price      of the common stock for the period.

 

Income      taxes.  The Company accounts for its income taxes in accordance with      Statement of Financial Accounting Standards No. 109 “Accounting for Income      Taxes”, which requires recognition of deferred tax assets and liabilities for      future tax consequences attributable to differences between the financial      statement carrying amounts of existing assets and liabilities and their      respective tax bases and tax credit carry-forwards. Deferred tax assets and      liabilities are measured using enacted tax rates expected to apply to taxable      income in the years in which those temporary differences are expected to be      recovered or settled. The effect on deferred tax assets and liabilities of      a      change in tax rates is recognized in income in the period that includes the      enactment date.

 

As      of      December 31, 2004, the Company has available net operating loss carryovers      of      approximately $4,000,000 that will expire in various periods through 2024.       Such losses may not be fully deductible due to the significant amounts of      non-cash service costs.  The Company has established a valuation allowance      for the full tax benefit of the operating loss carryovers due to the uncertainty      regarding realization.

 

Comprehensive      income (loss). The Company has no components of other comprehensive income.      Accordingly, net loss equals comprehensive loss for all periods.

 

 

----

Table          of Contents

 

**DAVISKIN,      INC.**

**(formerly      MW Medical, Inc.)**

**(A      Development State Company)**

 

Advertising      costs. Advertising costs incurred in the normal course of operations are      expensed as incurred.  No advertising costs have been incurred from      March      21, 2004 (date of inception) through September 30, 2005.

 

----

Table          of Contents

 

**DAVISKIN,      INC.**

**(formerly      MW Medical, Inc.)**

**(A      Development State Company)**

 

**        NOTES      TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)**

**(continued)**

 

2.              DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES

                 (continued)

 

Stock-based      compensation - The Company applies Accounting Principles Board (“APB”)      Opinion No. 25, “Accounting for Stock Issued to Employees, and Related      Interpretations,” in accounting for stock options issued to employees.       Under APB No. 25, employee compensation cost is recognized when estimated fair      value of the underlying stock on date of the grant exceeds the exercise price      of      the stock option.  For stock options and warrants issued to non-employees,      the Company applies SFAS No. 123, “Accounting for Stock-Based Compensation,”      which requires the recognition of compensation cost based upon the fair value      of      stock options at the grant date using the Black-Scholes option pricing      model.  For theperiod from March 21, 2004 (date of inception) through      September 30, 2005, there were no stock options and/or warrants granted to      employees.

 

In      order      to determine compensation on options issued to consultants, as well as fair      value disclosures for employee’s options, the fair value of each option granted      is estimated on the date of grant using the Black-Scholes option-pricing      model.

 

In      December 2003, the FASB issued SFAS No. 148, "Accounting for Stock-Based      Compensation-Transition and Disclosure." SFAS No. 148 amends the transition      and      disclosure provisions of SFAS No. 123. The Company is currently evaluating      SFAS      No. 148 to determine if it will adopt SFAS No. 123 to account for employee      stock      options using the fair value method and, if so, when to begin transition to      that      method.

 

3.              RELATED PARTY TRANSACTIONS

 

The      Company owes $200,000 to the former President of MW Medical.  The note      was      originally due December 31, 2004 and carries an interest rate of 10% per      annum.  Accordingly, interest of $25,000 has been recorded.       The      creditor has agreed to extend the due date of the note until December 31,      2005.

 

4.              STOCK ACTIVITY

 

During      the quarter, the Company sold no equity securities without registration under      the Securities Act of 1933.  All of the stock purchased prior to June      30,      2005 was issued in July 2005 and the liability of $105,500 was      reversed.

 

 

----

Table          of Contents

 

**DAVISKIN,        INC.**

**(formerly        MW Medical, Inc.)**

**(A        Development State Company)**

5.              EQUITY SECURITIES OFFERINGS

 

On      January 1, 2005, the Company commenced two separate equity securities      offerings.  The first offering (“offering one”) is targeted to Non-United      States investors and the second offering (“offering two”) is targeted to      domestic investors.  Both offerings allow the investor to purchase one      unit, consisting of two shares of common stock and one warrant to purchase      one      share of common stock at $4.50, exercisable for 24 months.  The purchase      price of each unit is $6.00.  The market price of the Company’s common      stock on the date of offering was $5.25.  There is no vesting period      for      the warrants; however, they are only exercisable for 24 months after the date      of      purchase.  During the quarter ended September 30, 2005, no units were      sold      from offering one and no units were sold from offering two.  As of      September 30, 2005, a total of 198,947 and 199,451 units have been sold from      offering one and offering two, respectively.

----

Table          of Contents

**Item      2.      Plan of      Operation**

**Forward-Looking      Statements**

**Plan      of Operation**

| 1.   | Development |
|----------------|-------------|

| 1.   | Eye                Cream; |
|----------------|---------------------------|

| 2.   | Revitalizing                Moisturizer; |
|----------------|------------------------------------------|

| 3.   | Daily                Moisturizer with an SPF rating for sun protection; |
|----------------|-------------------------------------------------------------------------|

| 4.   | Intensive                treatment serum; and |
|----------------|-----------------------------------------------|

----

Table          of Contents

----

Table          of Contents

| 2.   | Manufacture |
|----------------|-------------|

| a.   | the                shape and size of the product                containers; |
|----------------|-----------------------------------------------------------------------------|

| b.   | the                types of caps; |
|----------------|-----------------------------------|

| c.   | the                packaging; |
|----------------|-------------------------------|

| d.   | the                logo and label designs; and |
|----------------|------------------------------------------------|

| e.   | unit                cartons. |
|----------------|------------------------------|

| 3.   | Marketing                and Distribution |
|----------------|-------------------------------------------|

----

Table          of Contents

**Assets**

**Liabilities      and Stockholders Equity**

----

Table          of Contents

**Liquidity      and Capital Resources**

**Off      Balance Sheet Arrangements**

**Going      Concern**

**Revenue      Recognition**

**Non-Reliance      on Previously Issued Financial Statements**

** **

----

Table          of Contents

**Item      3.     Controls and Procedures**

----

Table          of Contents

**PART      II - OTHER INFORMATION**

**Item      1.     Legal      Proceedings**

**Item      2.     Unregistered Sales      of Equity Securities and Use of Proceeds**

**Item      3.     Defaults upon Senior      Securities**

**Item      4.     Submission of Matters      to a Vote of Security Holders**

**Item      5.     Other      Information**

**Item      6.      Exhibits**

| **Exhibit                Number** | **Description                of Exhibit**                                                                                                                                                                                                                |
|-----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 31.1                              | Certification                of Chief Executive Officer pursuant to 18                U.S.C. Section 1350, as adopted pursuant to Section 302 of the                Sarbanes-Oxley Act of 2002                                                           |
| 31.2                              | Certification                of Chief Financial Officer pursuant to 18                U.S.C. Section 1350, as adopted pursuant to Section 302 of the                Sarbanes-Oxley Act of 2002                                                           |
| 32.1                              | Certification                of Chief Executive Officer and Chief                Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted                pursuant                to Section 906 of the Sarbanes-Oxley Act of                2002 |

----

Table          of Contents

**SIGNATURES**

|   | **Joseph                Spellman**                                                                                                                                                                                                                                                                    |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                  |
| Date:  | November                21, 2005                                                                                                                                                                                                                                                                      |
|   |                                                                                                                                                                                                                                                                                                  |
|   | By:       /s/                Joseph Spellman                  **Joseph                Spellman**Title:**    Chief                Executive Officer** |